Anti Cd 20 Ocrevus denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Ocrevus as Duplicate Therapy — and Why You Can Appeal

A "duplicate therapy" denial means UnitedHealthcare's system or reviewer determined that you are already covered for — or have an active authorization for — another agent in the same therapeutic class as ocrelizumab (Ocrevus). In MS care, this most commonly occurs when a prior anti-CD20 agent or another disease-modifying therapy remains active on your profile, or when a transition between DMTs is not documented as a switch rather than an addition.

This denial is frequently the result of an administrative data error: a prior authorization for a discontinued therapy was never closed out, a pharmacy claim for a different DMT is still showing as active, or a care-transition note was not communicated to UHC's utilization management system. Even when the issue is clinical, it is fully appealable.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline shown on your Explanation of Benefits or denial letter (typically 180 days under ERISA §503 for employer plans, or under applicable state law for marketplace/individual plans).
• External review: ACA §2719 guarantees independent external review after an adverse internal decision. The standard window for filing is approximately four months from the date of final internal denial. Expedited review is available within 72 hours for urgent clinical circumstances.

## Concrete Steps and Timeline

1. Request the full denial letter. It must identify which therapy UHC considers duplicative and cite the specific policy provision. 2. Pull your active UHC authorizations and pharmacy claims history. Identify whether any prior DMT authorization was left open in error. 3. Contact UHC's provider services line — your prescribing neurologist's office can often resolve an administrative duplicate flag before a formal appeal is needed by submitting a corrected authorization or a note confirming the prior therapy has been discontinued. 4. If administrative correction fails or UHC declines, file the internal appeal with the documentation package below. 5. If the internal appeal is denied, file for external review before the four-month window closes.

## Documentation to Gather

• Discontinuation records for any prior DMT: Pharmacy records, infusion logs, and chart notes showing that any allegedly concurrent therapy has been stopped, including the date of last dose.
• Prescriber attestation of non-concurrent use: A letter from your neurologist explicitly stating that ocrelizumab is the sole DMT being prescribed and that no prior anti-CD20 or overlapping therapy is active.
• Diagnosis and treatment plan: Current chart notes documenting the clinical rationale for selecting ocrelizumab and the planned treatment approach.
• UHC authorization history: Print or request your full prior-authorization history from UHC to identify any open authorizations that need to be formally closed.
• Medical-necessity letter: If UHC's duplicate-therapy policy requires affirmative justification for using a particular DMT class, a neurologist letter addressing that requirement.

## Criteria-Mapping Structure

Retrieve UHC's coverage policy for ocrelizumab and its duplicate-therapy provisions. Map each requirement to your evidence:

| Policy Requirement | Your Evidence | |---|---| | No concurrent active authorization for overlapping DMT | Authorization history showing prior auth closed on [date] | | Documentation of prior therapy discontinuation | Last infusion/fill date [date], chart note confirming stop | | Prescriber attestation of sole-agent use | Neurologist letter dated [date] |

In many cases, a clear attestation letter from the neurologist — combined with corrected authorization records — resolves a duplicate-therapy denial at the internal level without needing to proceed to external review.